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INTRODUCTION
Cardiovascular disease occurs frequently in patients with
end-stage renal failure and is by far the main cause 
of death in these patients.1 In addition to classical 
cardiovascular risk factors such as hypertension and
hyperlipidaemia, hyperhomocysteinaemia, endothelial
dysfunction and increased oxidative stress have been
identified as important additional risk factors in patients
with end-stage renal disease.1,2
Hypotension during haemodialysis is a frequently
encountered clinical problem and has been reported to
occur in 20–50% of all patients on chronic haemodialy-
sis.3–6 The pathophysiology of haemodialysis-induced
hypotension is complex and multifactorial.6 Factors
involved are both patient-related (such as underlying
coronary artery disease), left ventricular (LV) diastolic
and systolic dysfunction, autonomic nervous system dys-
function and haemodialysis-related factors such as speed
and amount of ultrafiltration and the type and tempera-
ture of the dialysate used.1,6,7
DOBUTAMINE STRESS
ECHOCARDIOGRAPHY (DSE)
With DSE it is possible to assess LV function at rest and
the presence of coronary artery disease in a non-invasive
way.8 According to the guidelines of the American
Society of Echocardiography, the LV is subdivided into
16 segments.9 Each segment is evaluated for its wall
motion and thickening, both at rest and during DSE,
using a five-point score (normokinesia, mild hypokine-
sia, severe hypokinesia, akinesia and dyskinesia). In 
addition to systolic function, diastolic function can be
evaluated using Doppler flow measurements of early dias-
tolic (E wave) and late diastolic filling waves (A wave)
across the mitral valve and time intervals (isovolumetric
contraction and relaxation time).
At lower infusion rates (10 mg/kg/min) dobutamine
predominantly exerts an inotropic effect, whereas at
higher infusion rates the chronotropic effect prevails.
Hence, with the lower infusion rates information about
myocardial contractile reserve is obtained, while at
higher infusion rates information about the presence of
ischaemia is obtained. Ischaemia is detected by DSE as
new wall motion abnormalities.
The accuracy of DSE in diagnosing coronary artery
disease has been confirmed in a large number of patients,
including patients with end-stage renal disease with sig-
nificant coronary artery disease as diagnosed by coronary
angiography.10,11 Hypotension and cardiac arrhythmias
are the most frequently occurring side-effects of DSE.
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in cardiac index was considerably lower in the HP
patients.
When translating the results of DSE to the clinical
situation, we suggest that the inability of the cardiac
index to increase in response to sympathetic stress can
play a key role in the pathogenesis of haemodialysis-
induced hypotension. If haemodialysis-induced activa-
tion of the sympathetic nervous system does not lead to
an appropriate rise in cardiac output to maintain blood
pressure, further sympathetic discharge is likely to occur.
Eventually, owing to exhaustion, the autonomic nervous
system is no longer capable of maintaining this high level
of sympathetic tone and blood pressure will fall. The
cause of haemodialysis-induced hypotension in this 
situation is not primarily a consequence of failure of 
the autonomic nervous system but the consequence of
diminished myocardial responsiveness or myocardial
contractile reserve.
Although DSE can evoke hypotension in haemo-
dialysis patients, there is also limited evidence that infu-
sion of dobutamine during haemodialysis can actually
reduce the number of hypotensive episodes.14 Possibly,
this may be related to recruitment of contractile reserve
by dobutamine.
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The overall incidence of these side-effects is low, varying
between 2% and 3%,12 and appears not to be related to
the induction of ischaemia. Although reports are scarce,
adverse effects may occur more frequently in patients
with end-stage renal disease requiring haemodialysis. In
a reported study performed on haemodialysis patients,
DSE-induced hypotension (decrease in systolic blood
pressure > 40 mmHg) occurred in 6 out of 36 patients
(16%).13 In another study, atrial fibrillation was reported
to occur 5–10 times more often in haemodialysis than 
in non-haemodialysis patients. The advice is therefore 
to perform DSE prior to, not after, a haemodialysis
session when the patient is in a relatively hypervolaemic
condition.
Anti-anginal therapy, especially beta-blockers, is
usually skipped on the morning of the test and con-
tinued after the test. Beta-blockers shift the heart rate
dobutamine-response curve to the right, and contractile
reserve may be elicited only at a higher dobutamine
plasma level compared with patients without beta-
blockers. The evaluation of contractile reserve is not
influenced by beta-blockers provided that a prolonged
low-dose dobutamine infusion protocol is used. Com-
pared with the standard 3-min interval dose steps,
increasing dobutamine infusion dose with 10 mg/kg/min
up to 40 mg/kg/min, the prolonged low-dose dobutamine
infusion protocol has a 5 mg/kg/min infusion rate for 
5 min and a 10 mg/kg/min for 5 min. Thus, this protocol
induces a more reproducible and higher dobutamine
plasma level at the end of the low-dose (10 mg/kg/min)
infusion stage. For those patients not achieving target
heart rate at the end of the test, atropine is added. Fur-
thermore, care must be taken to ensure that electrolyte
abnormalities have been corrected before the test is 
performed.
Stroke volume during DSE can be calculated from
apical two- and four-chamber views using a modification
of Simpson’s rule. The principle of the Simpson’s rule 
is to divide the LV volume into slices of known thick-
ness. The volume of the LV is then equal to the sum of 
the volumes of the slices. Stroke volume is assessed by
the difference between end-diastolic and end-systolic
volume.9
In a recent study13 we applied DSE to evaluate cardiac
contractile reserve and the presence of myocardial ischae-
mia in hypertension-prone (HP) and hypertension-
resistant (HR) haemodialysis patients, matched for
volume status, cardiac risk factors and duration of
haemodialysis (Table 1). Dobutamine-induced ischae-
mia, as defined by new wall motion abnormalities, was
observed in only three of the HR and four of the 
HP patients. However, compared with the HR patients,
myocardial contractile reserve (increase in stroke index 
in response to dobutamine) was impaired in a consid-
erably larger proportion of the HP than HR patients. 
As a consequence of this reduced myocardial contrac-
tile reserve, the dobutamine-induced maximal increase 
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Table 1 Results of dobutamine stress echocardiography in
hypotension-prone (HP) and hypotension-resistant (HR)
haemodialysis patients
HR HP P-value
(n = 11) (n = 11)
Medication
Beta-blockers 12 6 0.04
Angiotensin-converting 9 5 NS
enzyme inhibitors
Noradrenaline (pg/mL) 429 ± 209 381 ± 174 NS
Ischaemia induced during 4 3 1.0
DSE
Hypotension during DSE 2 4 0.4
Stroke index (ml/m2)
Rest 39 ± 9 33 ± 9
Low-dose dobutamine 41 ± 12 31 ± 9 < 0.01
Peak dobutamine stress 36 ± 13 26 ± 10 < 0.01
Variables are expressed as mean values ± SD. DSE, dobutamine stress
echocardiography. Hypotension during DSE is a decrease of systolic
blood pressure > 40 mmHg. Stroke index is stroke volume corrected for
body surface area and expressed as ml/m2. Calculation of the stroke
volume is detailed in the text.
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